Newsletter | April 11, 2024

04.11.24 -- Drugging The Undruggable: Strategies And Future Directions

SPONSOR

The development of protein therapeutics faces critical challenges, from cell cloning inefficiencies to ensuring quality. Join our webinar to see how you can revolutionize your protein therapeutics development. See how the integration of VIPS® PRO technology and InstiGRO™ CHO supplements is setting new benchmarks in cloning success, enhancing both efficiency and quality in protein therapeutics. Ready to revolutionize your production methods? Join us to lead the change in protein therapeutics development. Register Now

FEATURED EDITORIAL

Drugging The Undruggable: Strategies And Future Directions

Progress with PROTACs and molecular glues hasn’t come without challenges, particularly in identifying the right chemistry starting point for drug development — a process known as hit discovery. This article looks at the role of CRISPR, screening assays, and more.

INDUSTRY INSIGHTS

PTFE Containment: Viable For Temperature-Sensitive Protection

Single-use cold-chain containers made with polytetrafluoroethylene fluoropolymers may be less susceptible to failure and breakage at cold temperatures.

Cell Culture Supplements To Accelerate Stable Cell Line Development

Review this demonstration where animal component-free Insti CHO and HEK cell culture supplements enable the industry to overcome cell culture limitations while meeting regulatory requirements.

Viral Clearance Considerations For Adeno-Associated Virus Vectors

There is no one-size-fits-all model for AAV gene therapy products when it comes to viral clearance studies. Here, we address some of the questions with respect to viral clearance studies for AAV vectors.

Lowering The Lipids Barrier: Accelerating RNA-LNP Drug Development

A key reason mRNA is considered a significant breakthrough is its potential to enable rapid and scalable drug development. Examine the hurdles that must be overcome to deliver on its promise.

COGs Process Economics For Autologous Cell Therapy

Analyze the cost distribution over time for autologous CAR T therapy manufacturing using process economics and additional insights. Discover how cell therapy manufacturers can combat these costs.

Establishing Flexibility For Parenteral Cleanroom Manufacturing

Cleanroom systems are purposely designed to simplify implementation of the aseptic manufacturing space that the industry needs to meet future sterile injectable capacity demand.

Validate CAR T Cell Enumeration By Flow Cytometry Using Cell Mimics

Delve into the details of a partnership that resulted in custom-ordered synthetic T cell mimics to solve challenges with lot-to-lot variability and long-term stability.

Quality Versus Quantity In T Cell Production

As more T cell therapies come to market, the quality and scale of treatments are set to improve further. See how technological advances have made it possible to produce high-quality T cells at scale.

Understanding Potency In Gene Therapy Development

Explore the importance of understanding potency in cell and gene therapy (CGT) development and the challenges in developing potency assays for CGT products.

How Level Of Touch Guides Clinical Trial Tools And Methods

To run clinical studies quickly, safely, and with high data integrity, it's effective to assess trials by degree of touch. Discover how different trial types are suited to the application of different tools and methods.

Universal AAV Enhancer For Improved Viral Titers, Quality, And Costs

AAV therapies require high quality and high titers of viral genomes per dosage, prompting the need for a more efficient AAV manufacturing method to reduce overall costs.

SOLUTIONS

Accurate Cell Culture Characterization

Bioprocess Powder Bags

Emulate Contract Research Services

jetMESSENGER: mRNA Transfection Reagent

Flexibility For Advanced Manufacturing Facilities With PODs

Connect With Cell & Gene: